The new trial investigated the role of the Pro version of the mySugr app, a digital diabetes logbook which Roche acquired along with its developer in 2017 and – in a defining moment for digital ...

Roche Diagnostics is cutting an unspecified number of jobs at two locations in Central Indiana as it struggles to cope with changing conditions in the diabetes care market. Company spokesman Todd ...

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income countries.

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

"Today we're proud to announce that we're joining the Roche family to help create an open digital diabetes ecosystem that revolves entirely around people with diabetes." The company says it will ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

52 million Europeans are living with diabetes, and in Germany alone, there are 6 to 8 million documented cases. That number is projected to grow. German-based Roche Diagnostics is dedicated to ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Roche shares gained 5.5%. Zealand is testing petrelintide, opens new tab in overweight or obese individuals without type 2 diabetes in a mid-stage study. Petrelintide belongs to a class of drugs ...